These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17227618)

  • 1. Modification of the crystal habit of celecoxib for improved processability.
    Banga S; Chawla G; Varandani D; Mehta BR; Bansal AK
    J Pharm Pharmacol; 2007 Jan; 59(1):29-39. PubMed ID: 17227618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V; Perioli L; Marmottini F; Rossi C
    Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal modification of dipyridamole using different solvents and crystallization conditions.
    Adhiyaman R; Basu SK
    Int J Pharm; 2006 Sep; 321(1-2):27-34. PubMed ID: 16842943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
    Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
    PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid-state properties and crystallization behavior of PHA-739521 polymorphs.
    Sun CC
    Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid dispersion of spironolactone with porous silica prepared by the solvent method.
    Uchino T; Yasuno N; Yanagihara Y; Suzuki H
    Pharmazie; 2007 Aug; 62(8):599-603. PubMed ID: 17867555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of differential surface molecular environment on the interparticulate bonding strength of celecoxib crystal habits.
    Modi SR; Khomane KS; Bansal AK
    Int J Pharm; 2014 Jan; 460(1-2):189-95. PubMed ID: 24148668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
    Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
    Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of microcrystals for enhanced dissolution rate of celecoxib.
    Lakshmi K; Reddy MP; Kaza R
    Curr Drug Discov Technol; 2013 Dec; 10(4):305-14. PubMed ID: 24074306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.
    Gupta VR; Mutalik S; Patel MM; Jani GK
    Acta Pharm; 2007 Jun; 57(2):173-84. PubMed ID: 17507314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties.
    Bukovec P; Benkic P; Smrkolj M; Vrecer F
    Pharmazie; 2016 May; 71(5):263-8. PubMed ID: 27348970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of celecoxib nanosuspension formulation and transformation into tablets.
    Dolenc A; Kristl J; Baumgartner S; Planinsek O
    Int J Pharm; 2009 Jul; 376(1-2):204-12. PubMed ID: 19426794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.
    Albers J; Alles R; Matthée K; Knop K; Nahrup JS; Kleinebudde P
    Eur J Pharm Biopharm; 2009 Feb; 71(2):387-94. PubMed ID: 18951978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of α-relaxation on crystallization of amorphous celecoxib above T(g) probed by dielectric spectroscopy.
    Dantuluri AK; Amin A; Puri V; Bansal AK
    Mol Pharm; 2011 Jun; 8(3):814-22. PubMed ID: 21534589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques.
    Homayouni A; Sadeghi F; Varshosaz J; Afrasiabi Garekani H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2014 Oct; 122():591-600. PubMed ID: 25124835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of physicomechanical properties of carbamazepine by recrystallization at different pH values.
    Javadzadeh Y; Mohammadi A; Khoei NS; Nokhodchi A
    Acta Pharm; 2009 Jun; 59(2):187-97. PubMed ID: 19564143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.
    Remenar JF; Peterson ML; Stephens PW; Zhang Z; Zimenkov Y; Hickey MB
    Mol Pharm; 2007; 4(3):386-400. PubMed ID: 17497886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol.
    Sai Gouthami K; Kumar D; Thipparaboina R; Chavan RB; Shastri NR
    Int J Pharm; 2015 Aug; 491(1-2):26-34. PubMed ID: 26068197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.